Experts Debate: Treatment Decisions in Relapsed/Refractory Multiple Myeloma

Registration

Date: Friday, December 10, 2021
Time: 11:00 AM - 1:30 PM ET
Live Meeting Location: Georgia World Congress Center - 285 Andrew Young International Blvd NW, Atlanta, GA 30313
Symposium Room:
Georgia Ballroom 2, Level 3


Unable to attend in person? Live stream options will be available. REGISTER TO ATTEND VIRTUALLY NOW!

Symposium Overview
This satellite symposium will take place preceding the ASH 2021 Annual Meeting and will be presented by four renowned experts actively engaged in the care of patients with multiple myeloma. 

Target Audience
This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM and who attend the ASH Annual Meeting.

Learning Objectives
After participating in the activity, participants should be better able to:

  • Incorporate minimal residual disease assessment when evaluating prognosis and potential relapse
  • Evaluate treatment approaches for patients with relapsed and/or refractory MM, specifically the decision to include a monoclonal bispecific antibody, or antibody-drug conjugate, CAR T cell therapy, and combination with other agents for triplet therapy
  • Develop strategies to mitigate treatment-related adverse events that may occur during the care of patients with RR MM
  • Discuss the results of clinical trials that are investigating emerging novel agents in patients with RR MM

Continuing Education
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
The University of Nebraska Medical Center designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Agenda
11:00 am     Welcome, Introductions, and Presession Survey - Dr. Sagar Lonial

11:10 am     What is the Optimal Partner for CD38 Therapy in First Relapse?
IMID - Dr. Suzanne Lentzsch
PI - Dr. Saad Usmani
Panel Discussion and Rebuttals 

11:40 am     Is MRD Assessment Useful for Treatment Decisions?
Yes - Dr. Jeffrey Wolf
No - Dr. Sagar Lonial
Panel Discussion and Rebuttals 

12:10 pm    What is the Optimal Class of Agents for Triple Class Refractory MM?
Immunotherapy - Dr. Sagar Lonial
Small Molecules - Dr. Saad Usmani
Panel Discussion and Rebuttals 

12:40 pm    What is the Optimal Immunotherapy for Targeting BCMA?
CAR T-Cells - Dr. Suanne Letzsch
Bispecific Antibodies/ADCs - Dr. Jeffrey Wolf
Panel Discussion and Rebuttals
 

1:10 pm      Audience Q&A with the Clinical Experts - Moderated by Dr. Sagar Lonial

1:20 pm     Recap of Key Points and Post-Session Survey - Dr. Sagar Lonial

1:30 pm     Conclusion



Chair
Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Faculty

Suzanne Lentzsch, MD, PhD
Professor of Medicine at Columbia Universityt
Director, Multiple Myeloma and Amyloidosis Service

Herbert Irving Comprehensive Cancer Center
Columbia University
New York, New York

Saad Usmani, MD, MBA, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Jeffrey Wolf, MD
Clinical Professor, Department of Medicine
Director, Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Disclosure Information
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality. 

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations. 

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. 

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.  


The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:   

 
Faculty 

Sagar Lonial, MD, FACP
Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Bluebird, Celgene Corporation, Genentech, Novartis, Sanofi, Takeda Oncology
Other: Board of Directors TG Therapeutics with stock

Suzanne Lentzsch, MD, PhD
Consulting Fees: Janssen, Celularity, Abbvie, GSK, Takeda, Karyopharm, Sanofi, Oncopeptides
Research Funding: Karyopharm, Sanofi
Advisor: Caelum Biosciences

Stock Owner: Caelum Biosciences, Magenta, Kadon

Saad Usmani, MD, MBA, FACP

Consulting Fees:  Amgen, Bristol-Myers Squibb Company, Celgene Corporation, EdoPharma, GSK, Janssen, Sanofi, Seattle Genetics, 
SecuraBio, SkylineDX, Takeda, TeneoBio

Research Funding: Amgen, Array Biopharma, Bristol-Myers Squibb Company, Celgene Corporation, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda

Jeffrey Wolf, MD
Consulting Fees: Adaptive Biotechnologies, Teneobio, Sanofi, Amgen


Planning Committee​
The following planning committee members have nothing to disclose:​
UNMC: Brenda Ram, CMP, CHCP​
Bio Ascend: Jennifer Bechan, CMP, HMCC;  Dru Dace, PhD; Kraig Steubing

Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme

Friday Satellite Symposium on Multiple Myeloma, preceding the 63rd ASH Annual Meeting and Exposition.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.